Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of Patients With Acute Renal Failure on CVVH
This study is currently recruiting participants.
Verified by Children's Healthcare of Atlanta, June 2007
Sponsored by: Children's Healthcare of Atlanta
Information provided by: Children's Healthcare of Atlanta
ClinicalTrials.gov Identifier: NCT00207909
  Purpose

Acute kidney failure is common in children in the Pediatric Intensive Care Unit (PICU). You are being asked to participate in this study because your child is being treated for kidney failure with continuous veno-venous hemofiltration (CVVH). CVVH is a continuous, gentle form of removing excess fluids and small wastes from the blood, similar to kidney dialysis (artificial kidney). It is an accepted therapy for temporary support of kidney failure. In some patients with acute kidney failure, beginning CVVH is followed by a temporary decrease of urine output. The reason why this happens is currently unknown. The purpose of this study is to determine why this happens.


Condition
Renal Failure

MedlinePlus related topics: Kidney Failure Urine and Urination
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study
Official Title: The Role of Hemodynamics, Cytokine Response, and Modulators of Apoptosis on Urine Output in Patients With Acute Renal Failure on CVVH

Further study details as provided by Children's Healthcare of Atlanta:

Estimated Enrollment: 40
Study Start Date: February 2005
Detailed Description:

Acute renal failure is common in children in the pediatric intensive care unit. Renal replacement therapies such as peritoneal dialysis (PD), intermittent hemodialysis (IHD), and continuous venovenous hemofiltration (CVVH) have been used in the management of acute renal failure. CVVH is becoming increasingly utilized in pediatric acute renal failure. However, in patients who have acute renal failure, the institution of CVVH is often followed by a progression to oliguria or anuria. The underlying pathophysiology of this change is unknown. We believe that this progression is influenced by changes in the renin-angiotensin axis, cytokine response, and other modifiers of renal hemodynamics. By serially measuring components of those systems, this study will attempt to elucidate the pathophysiology of the decreased urine output seen with institution of CVVH. Once this process is understood, future studies should focus on prevention and treatment of this complication.

General Hypothesis

The decrease in urine output seen after the initiation of CVVH is associated with increased angiotensin converting enzyme (ACE) levels, increased renin activity, increased angiotensin II levels, increased atrial naturetic peptide (ANP) levels, increased endothelin-1 levels, increased arginine vasopressin (AVP) levels, and alterations of cytokine levels and modulators of apoptosis.

  Eligibility

Ages Eligible for Study:   5 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The general goal of patient selection is to enroll all children for whom CVVH is instituted.

Inclusion criteria:

Age

  • 6 months -18 years old
  • Patients less than 6 months of age on ECMO (addendum #1)

Indication for CVVH: including, but not limited to :

  • Acute Renal Failure
  • Oliguria
  • Anuria
  • Hyperkalemia
  • Severe acidemia
  • Azotemia
  • Pulmonary Edema
  • Uremic complications
  • Severe electrolyte abnormalities
  • Drug overdose with a filterable toxin
  • Anasarca
  • Rhabdomyolysis

Exclusion Criteria:

  • Age

    • Less than 6 months old (unless on ECMO)
    • Greater than 18 years old Weight
    • Less than 5 kilograms (unless ON ECMO) Location
    • Cardiac Intensive Care Unit
    • Neonatal Intensive Care Unit

Non-adherence:

Inability or unwillingness of the legal guardian to provide consent or inability or unwillingness of the child to provide assent

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00207909

Contacts
Contact: Matthew Paden, MD 404-785-1750 matthew.paden@choa.org
Contact: Kristine M Rogers, RN 404-785-1215 kristine.rogers@choa.org

Locations
United States, Georgia
Children's Healthcare of Atlanta at Egleston Recruiting
Atlanta, Georgia, United States, 30322
Contact: Matt Paden, MD     404-785-1750     matthew.paden@choa.org    
Contact: Krstine M Rogers, RN     404-785-1215     kristine.rogers@choa.org    
Principal Investigator: James D Fortenberry, MD            
Principal Investigator: Matt Paden, MD            
Sponsors and Collaborators
Children's Healthcare of Atlanta
Investigators
Principal Investigator: James D Fortenberry, MD Children's Healthcare of Atlanta
  More Information

Study ID Numbers: 04-114, 06585
Study First Received: September 13, 2005
Last Updated: June 13, 2007
ClinicalTrials.gov Identifier: NCT00207909  
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Healthcare of Atlanta:
Acute Renal Failure
Contiuous Veno Venous Hemofiltration

Study placed in the following topic categories:
Renal Insufficiency
Urologic Diseases
Renal Insufficiency, Acute
Kidney Diseases
Kidney Failure, Acute
Kidney Failure

ClinicalTrials.gov processed this record on January 16, 2009